{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreic72ybe66bptzv6ofsjvb4rbstdwippbnec6jxggshst4nmabycfi",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3me6lv2pgrp22"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibnbbiprl7qbpevztwmor5xrdayfe6ijfw6mlwgl3sagye5anfoby"
    },
    "mimeType": "image/jpeg",
    "size": 12221
  },
  "path": "/2026/02/06/kelun-biotech-announces-fourth-indication-for-sacituzumab-tirumotecan-sac-tmt-approved-by-nmpa-in-hr-her2-breast-cancer/",
  "publishedAt": "2026-02-06T09:00:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "CHENGDU, China, Feb. 6, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company”, 6990.HK) announced that a new indication application for its TROP2-directed ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) has been approved by the National Medical Products Administration (NMPA) of China for treatment of adult patients with unresectable or […]",
  "title": "Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer"
}